Repertoire Immune Medicines Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Repertoire Immune Medicines is a mid-sized biotechnology company focused on developing therapies that harness the human T cell repertoire to target cancer, infections, and autoimmune disease. Its DECODE platform aims to map the full range of T cell receptor–antigen interactions across the immune synapse, detailing the TCR-epitope pairing, HLA context, and T cell phenotype to inform new immune-based medicines. By translating these insights into therapeutic candidates, the company seeks to advance treatments across autoimmune, infectious, and oncologic indications. Headquartered in Cambridge, Massachusetts, with additional activity in Zurich, the company collaborates with other researchers and pharmaceutical partners to bring its approaches into development programs. A notable recent development is a collaboration and license agreement with Genentech announced in April 2025 to discover and develop T cell–targeted medicines for autoimmune disease.